<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03045562</url>
  </required_header>
  <id_info>
    <org_study_id>GV-MD-CT201602</org_study_id>
    <nct_id>NCT03045562</nct_id>
  </id_info>
  <brief_title>Effects of Salvianolate Injection on Myocardial Microcirculation in Patients With Acute STEMI After Primary PCI</brief_title>
  <acronym>SISTEMI</acronym>
  <official_title>Effects of Salvianolate Injection on Myocardial Microcirculation in Patients With Acute ST Segment Elevation Myocardial Infarction After Primary PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Valley Group of China</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Valley Group of China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the influence of Salvianolate injection on myocardial microcirculation perfusion
      in subjects with STEMI who underwent primary PCI
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, double-blind and controlled study.536 subjects of STEMI
      who underwent primary PCI within the first 12 hours will be enrolled.all patients were
      assigned to receive 300mg of asprin and ≥300mg of clopidogrel as loading dose,and following
      100mg and 75mg once daily respectively.Patients were assigned to receive Salvianolate
      injection or 0.9% sodium chloride injection in catherter room setting,and following similar
      medicine once daily respectively for 7 days.Myocardial circulation perfusion will be checked
      with mmediate coronary angiography parameters,ECG,echocardiographic，CK-MB.The major adverse
      cardiovascular events will be observed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TIMI flow grade</measure>
    <time_frame>an average of 2 hours</time_frame>
    <description>Use TIMI flow grade to evaluate myocardial circulation perfusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TIMI myocardial perfusion grade</measure>
    <time_frame>an average of 2 hours</time_frame>
    <description>Use TIMI myocardial perfusion grade to evaluate myocardial circulation perfusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ST-segment resolution</measure>
    <time_frame>up to 90 minutes</time_frame>
    <description>Use ST-segment resolution to evaluate the epicardial blood flow perfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial contrast echocardiograph</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Use myocardial contrast echocardiograph to evaluate the myocardial microcirculation perfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>creatine kinase isoenzyme</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Use creatine kinase isoenzyme to evaluate myocardial infarct size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major adverse cardiovascular events</measure>
    <time_frame>an average of 30 days</time_frame>
    <description>all-caused death, re-infarction, target vessel revascularization, stroke</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">536</enrollment>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be assigned to receive 100ml of normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Patients will be assigned to receive 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>0.9% sodium chloride solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salvianolate injection</intervention_name>
    <description>Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Salvianolate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent must be obtained prior to any study procedure.

          2. Age&gt;18 years.

          3. Subjects of STEMI who underwent primary PCI within the first 12 hours.

        Exclusion Criteria:

          1. Allergic to Salvianolate injection

          2. Mechanical complications

          3. History of severe renal or hepatic insufficiency

          4. Pregnant or breastfeeding women

          5. Pool compliance,greater risks result from the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongying Liu, doctor</last_name>
    <email>yuyangxian021@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongying Liu, doctor</last_name>
      <phone>+86 21 64041990</phone>
      <email>yuyangxian021@163.com</email>
    </contact>
    <investigator>
      <last_name>Junbo Ge, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2017</study_first_submitted>
  <study_first_submitted_qc>February 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

